Monte Rosa reports positive Phase 1 GFORCE-1 results for MRT-8102 in elevated CVD-risk subjects
GLUE•GLUE•GLUE•GLUE•Monte Rosa Therapeutics reported positive Phase 1 results for MRT-8102 in obese subjects with elevated cardiovascular risk. Treatment lowered multiple inflammatory and clotting-related disease drivers toward healthy-volunteer levels, with no serious adverse events reported.
Monte Rosa Therapeutics reported positive results from its Phase 1 GFORCE-1 study of MRT-8102 in obese subjects with elevated cardiovascular risk. Treatment lowered multiple inflammatory and clotting-related disease drivers toward levels seen in healthy volunteers; its safety profile appeared comparable to placebo, with no serious adverse events reported.
Monte Rosa plans Phase 2 studies in coronary artery disease in the first half of 2027, along with additional mid-stage trials in gout and hidradenitis suppurativa.
